[Skip to Content]
[Skip to Content Landing]
Invited Commentary
October 2015

Hypofractionation for Early-Stage Breast CancerNo More Excuses

Author Affiliations
  • 1Harvard Radiation Oncology Program, Boston, Massachusetts
  • 2Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham & Women’s Cancer Center, Harvard Medical School, Boston, Massachusetts
JAMA Oncol. 2015;1(7):941-942. doi:10.1001/jamaoncol.2015.2605

In the last 5 years, mature follow-up analyses of randomized trials have been published offering fundamental insight into questions of dose and fractionation in breast cancer radiotherapy. Two landmark studies from the United Kingdom1 and Canada2 randomized women with early-stage breast cancer undergoing adjuvant breast irradiation to either conventionally fractionated radiotherapy over 5 weeks (50 Gy in 25 fractions) or hypofractionated radiotherapy over 3 to 4 weeks (40.0-42.5 Gy to the whole breast in 15-16 fractions). These trials showed comparable rates of local control and overall survival at 10 years.

First Page Preview View Large
First page PDF preview
First page PDF preview